BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

337 related articles for article (PubMed ID: 29484475)

  • 1. Medullary Thyroid Carcinoma: Survival Analysis and Evaluation of Mutation-Specific Immunohistochemistry in Detection of Sporadic Disease.
    Jayakody S; Reagh J; Bullock M; Aniss A; Clifton-Bligh R; Learoyd D; Robinson B; Delbridge L; Sidhu S; Gill AJ; Sywak M
    World J Surg; 2018 May; 42(5):1432-1439. PubMed ID: 29484475
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NRASQ61R Mutation-specific Immunohistochemistry Also Identifies the HRASQ61R Mutation in Medullary Thyroid Cancer and May Have a Role in Triaging Genetic Testing for MEN2.
    Reagh J; Bullock M; Andrici J; Turchini J; Sioson L; Clarkson A; Watson N; Sheen A; Lim G; Delbridge L; Sidhu S; Sywak M; Aniss A; Shepherd P; Ng D; Oei P; Field M; Learoyd D; Robinson BG; Clifton-Bligh RJ; Gill AJ
    Am J Surg Pathol; 2017 Jan; 41(1):75-81. PubMed ID: 27635947
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genomics and Epigenomics of Medullary Thyroid Carcinoma: From Sporadic Disease to Familial Manifestations.
    Barletta JA; Nosé V; Sadow PM
    Endocr Pathol; 2021 Mar; 32(1):35-43. PubMed ID: 33492588
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Revisiting the genotype-phenotype correlation in children with medullary thyroid carcinoma: A report from the GPOH-MET registry.
    Kuhlen M; Frühwald MC; Dunstheimer DPA; Vorwerk P; Redlich A
    Pediatr Blood Cancer; 2020 Apr; 67(4):e28171. PubMed ID: 31925938
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Nationwide Study of Multiple Endocrine Neoplasia Type 2A in Norway: Predictive and Prognostic Factors for the Clinical Course of Medullary Thyroid Carcinoma.
    Opsahl EM; Brauckhoff M; Schlichting E; Helset K; Svartberg J; Brauckhoff K; Mæhle L; Engebretsen LF; Sigstad E; Grøholt KK; Akslen LA; Jørgensen LH; Varhaug JE; Bjøro T
    Thyroid; 2016 Sep; 26(9):1225-38. PubMed ID: 27400880
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of CDKN2C Copy Number in Sporadic Medullary Thyroid Carcinoma.
    Grubbs EG; Williams MD; Scheet P; Vattathil S; Perrier ND; Lee JE; Gagel RF; Hai T; Feng L; Cabanillas ME; Cote GJ
    Thyroid; 2016 Nov; 26(11):1553-1562. PubMed ID: 27610696
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Distribution of RET Mutations and Evaluation of Treatment Approaches in Hereditary Medullary Thyroid Carcinoma in Turkey.
    Aydoğan Bİ; Yüksel B; Tuna MM; Navdar Başaran M; Akkurt Kocaeli A; Ertörer ME; Aydın K; Güldiken S; Şimşek Y; Cihan Karaca Z; Yılmaz M; Aktürk M; Anaforoğlu İ; Kebapçı N; Duran C; Taşlıpınar A; Kulaksızoğlu M; Gürsoy A; Dağdelen S; Erdoğan MF
    J Clin Res Pediatr Endocrinol; 2016 Mar; 8(1):13-20. PubMed ID: 26758973
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prophylactic thyroidectomy in multiple endocrine neoplasia 2 (MEN2) patients with the C634Y mutation: A long-term follow-up in a large single-center cohort.
    Febrero B; Rodríguez JM; Ríos A; Segura P; Pérez-Sánchez B; Torregrosa N; Hernández AM; Parrilla P
    Eur J Surg Oncol; 2019 Apr; 45(4):625-630. PubMed ID: 30366876
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-Term Outcomes and Aggressiveness of Hereditary Medullary Thyroid Carcinoma: 40 Years of Experience at One Center.
    Raue F; Bruckner T; Frank-Raue K
    J Clin Endocrinol Metab; 2019 Oct; 104(10):4264-4272. PubMed ID: 31145454
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The prevalence of somatic RAS mutations in medullary thyroid cancer - a Polish population study.
    Oczko-Wojciechowska M; Pfeifer A; Rusinek D; Pawlaczek A; Zebracka-Gala J; Kowalska M; Kowal M; Swierniak M; Krajewska J; Gawlik T; Chmielik E; Czarniecka A; Szpak-Ulczok S; Jarząb B
    Endokrynol Pol; 2015; 66(2):121-5. PubMed ID: 25931041
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hereditary Medullary Thyroid Cancer Genotype-Phenotype Correlation.
    Frank-Raue K; Raue F
    Recent Results Cancer Res; 2015; 204():139-56. PubMed ID: 26494387
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evidence of a low prevalence of RAS mutations in a large medullary thyroid cancer series.
    Ciampi R; Mian C; Fugazzola L; Cosci B; Romei C; Barollo S; Cirello V; Bottici V; Marconcini G; Rosa PM; Borrello MG; Basolo F; Ugolini C; Materazzi G; Pinchera A; Elisei R
    Thyroid; 2013 Jan; 23(1):50-7. PubMed ID: 23240926
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Medullary Thyroid Carcinoma in MEN2A: ATA Moderate- or High-Risk RET Mutations Do Not Predict Disease Aggressiveness.
    Voss RK; Feng L; Lee JE; Perrier ND; Graham PH; Hyde SM; Nieves-Munoz F; Cabanillas ME; Waguespack SG; Cote GJ; Gagel RF; Grubbs EG
    J Clin Endocrinol Metab; 2017 Aug; 102(8):2807-2813. PubMed ID: 28609830
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The characterization of pheochromocytoma and its impact on overall survival in multiple endocrine neoplasia type 2.
    Thosani S; Ayala-Ramirez M; Palmer L; Hu MI; Rich T; Gagel RF; Cote G; Waguespack SG; Habra MA; Jimenez C
    J Clin Endocrinol Metab; 2013 Nov; 98(11):E1813-9. PubMed ID: 24030942
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic Significance of Circulating RET M918T Mutated Tumor DNA in Patients With Advanced Medullary Thyroid Carcinoma.
    Cote GJ; Evers C; Hu MI; Grubbs EG; Williams MD; Hai T; Duose DY; Houston MR; Bui JH; Mehrotra M; Waguespack SG; Busaidy NL; Cabanillas ME; Habra MA; Luthra R; Sherman SI
    J Clin Endocrinol Metab; 2017 Sep; 102(9):3591-3599. PubMed ID: 28911154
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic variables and calcitonin in medullary thyroid cancer.
    Clark JR; Fridman TR; Odell MJ; Brierley J; Walfish PG; Freeman JL
    Laryngoscope; 2005 Aug; 115(8):1445-50. PubMed ID: 16094121
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Occurrence of the Cys611Tyr mutation and a novel Arg886Trp substitution in the RET proto-oncogene in multiple endocrine neoplasia type 2 families and sporadic medullary thyroid carcinoma cases originating from the central region of Portugal.
    Prazeres HJ; Rodrigues F; Figueiredo P; Naidenov P; Soares P; Bugalho MJ; Lacerda M; Campos B; Martins TC
    Clin Endocrinol (Oxf); 2006 Jun; 64(6):659-66. PubMed ID: 16712668
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High prevalence of exon 8 G533C mutation in apparently sporadic medullary thyroid carcinoma in Greece.
    Sarika HL; Papathoma A; Garofalaki M; Vasileiou V; Vlassopoulou B; Anastasiou E; Alevizaki M
    Clin Endocrinol (Oxf); 2012 Dec; 77(6):857-62. PubMed ID: 22676047
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of mitochondrial DNA transversion mutations with familial medullary thyroid carcinoma/multiple endocrine neoplasia type 2 syndrome.
    Abu-Amero KK; Alzahrani AS; Zou M; Shi Y
    Oncogene; 2006 Feb; 25(5):677-84. PubMed ID: 16205644
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-Term Outcome After Surgery for Medullary Thyroid Carcinoma: A Single-Center Experience.
    Torresan F; Cavedon E; Mian C; Iacobone M
    World J Surg; 2018 Feb; 42(2):367-375. PubMed ID: 29134313
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.